Episode Synopsis "E2: Evaluating Safety and Efficacy of Treatment for Wet AMD"

Peter Kaiser, MD, and Timothy Murray, MD, MBA, discuss the HAWK and HARRIER phase 3 studies evaluating the safety and efficacy of brolucizumab for wet AMD.

Listen "E2: Evaluating Safety and Efficacy of Treatment for Wet AMD"

More episodes of the podcast Retinal Physician Insider

• E13: Key Findings from Recent Protocols for DRCR
• E12: Treatment of Non-proliferative diabetic retinopathy in the Absence of DME
• E11: The Treatment of Diabetic Retinopathy
• E10: The Port Delivery System and Wet AMD
• E9: Treatment Options in the Covid Era
• E8: The Challenge of Treating with Persistent Fluid
• E7: Genentech’s New Port Delivery System
• E6: Closing Macular Holes
• E5: Changes in Diabetic Retinopathy
• E4: New Therapies and Clinical Trials for AMD
• E3: Choosing Anti-VEGF Treatment for Patients with AMD
• E2: Evaluating Safety and Efficacy of Treatment for Wet AMD
• E1: Age-related Macular Degeneration